CD47 and cancer: Blockade of CD47 interaction with SIRPα ligands on phagocytes enhances cancer cell clearance by phagocytes such as macrophages and dendritic cells (DCs) to activate innate immune responses, a process that promotes antigen-presenting cells antigen cross-presentation, which leads to the initiation of T cells, which activate the adaptive antitumor immune response [65, 66].